Prior Negative Biopsy, PSA Density, and Anatomic Location Impact Cancer Detection Rate of MRI-Targeted PI-RADS Index Lesions
Current Oncology · 2024
DOI: 10.3390/curroncol31080329 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Ahmad N Alzubaidi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Image-Guided Biopsy, Magnetic Resonance Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Penn State Health No Shave November Education and Research Fund.
Abstract (Originalsprache)
Background
MRI fusion prostate biopsy has improved the detection of clinically significant prostate cancer (CSC). Continued refinements in predicting the pre-biopsy probability of CSC are essential for optimal patient counseling. We investigated potential factors related to improved cancer detection rates (CDR) of CSC in patients with PI-RADS ≥ 3 lesions.
Methods
The pathology of 980 index lesions in 980 patients sampled by transrectal mpMRI-targeted prostate biopsy across four medical centers between 2017–2020 was reviewed. PI-RADS lesion distribution included 291 PI-RADS-5, 374 PI-RADS-4, and 315 PI-RADS-3. We compared CDR of index PI-RADS ≥ 3 lesions based on location (TZ) vs. (PZ), PSA density (PSAD), and history of prior negative conventional transrectal ultrasound-guided biopsy (TRUS).
Results
Mean age, PSA, prostate volume, and level of prior negative TRUS biopsy were 66 years (43–90), 7.82 ng/dL (5.6–11.2), 54 cm3 (12–173), and 456/980 (46.5%), respectively. Higher PSAD, no prior history of negative TRUS biopsy, and PZ lesions were associated with higher CDR. Stratified CDR highlighted significant variance across subgroups. CDR for a PI-RADS-5 score, PZ lesion with PSAD ≥ 0.15, and prior negative biopsy was 77%. Conversely, the CDR rate for a PI-RADS-4 score, TZ lesion with PSAD < 0.15, and prior negative biopsy was significantly lower at 14%.
Conclusions
For index PI-RADS ≥ 3 lesions, CDR varied significantly based on location, prior history of negative TRUS biopsy, and PSAD. Such considerations are critical when counseling on the merits and potential yield of prostate needle biopsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA.
- Pennsylvania State College of Medicine, Hershey, PA 17033, USA.
- Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.
- Department of Urology, University of Florida College of Medicine, Gainesville, FL 32611, USA.
- UPMC Central PA Hospital, Camphill, PA 17011, USA.
ORCID-Profile: Max Yudovich
Förderung
- Penn State Health No Shave November Education and Research Fund
Zitieren
APA
Alzubaidi, A. N., Zheng, A., Said, M., Fan, X., Maidaa, M., Owens, R. G., Yudovich, M., Pursnani, S., Owens, R. S., Stringer, T., Tracy, C. R., & Raman, J. D. (2024). Prior Negative Biopsy, PSA Density, and Anatomic Location Impact Cancer Detection Rate of MRI-Targeted PI-RADS Index Lesions. Current Oncology. https://doi.org/10.3390/curroncol31080329
Vancouver
Alzubaidi AN, Zheng A, Said M, Fan X, Maidaa M, Owens RG, et al. Prior Negative Biopsy, PSA Density, and Anatomic Location Impact Cancer Detection Rate of MRI-Targeted PI-RADS Index Lesions. Current Oncology. 2024. doi:10.3390/curroncol31080329
BibTeX
@article{Alzubaidi2024,
author = {Alzubaidi, Ahmad N and Zheng, Amy and Said, Mohammad and Fan, Xuanjia and Maidaa, Michael and Owens, R Grant and Yudovich, Max and Pursnani, Suraj and Owens, R Scott and Stringer, Thomas and Tracy, Chad R and Raman, Jay D},
title = {Prior Negative Biopsy, PSA Density, and Anatomic Location Impact Cancer Detection Rate of MRI-Targeted PI-RADS Index Lesions},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31080329}
}
EUVIMED